Novo Nordisk A/S: The Healthcare Titan with Robust Financial Health

Discover the strength of healthcare titan Novo Nordisk in our latest blog! Strong sales and EPS are just the start.


7/8/20231 min read

Greetings, finance aficionados! Today, we're shining the spotlight on Novo Nordisk A/S (NYSE: NVO), a giant in the healthcare sector. Let's dissect their numbers, shall we?

First off, let's take a peek at their Earnings Per Share (EPS) performance. In the last quarter, the company reported a robust growth of 38%, marking the third quarter of consecutive EPS growth. That's not all; the company has consistently grown its EPS annually for the past four years. For the current quarter, the EPS is expected to increase by a strong 65%, and for the year, an impressive growth of 47% is projected.

Now, let's move on to sales. The last quarter saw an increase of 24%, with a healthy three-year growth rate of 12%. Novo Nordisk also boasts a high pre-tax margin of 39% and a notable Return on Equity (ROE) of 68.7%. Plus, they've managed to keep their Debt-to-Equity ratio at a modest 29%.

Currently, Novo Nordisk's share price is $161.83, slightly off its 52-week high by 6%. It's trading just 1% below its 50-day moving average, and its 50-day average volume stands at 1.3 million.

With a hefty market cap of $364.1 billion and an increase in fund ownership over the past seven quarters, Novo Nordisk is flexing its muscles in the financial fitness arena. And we think it's worth watching!